

2025 Current Fiscal Year Report: National Vaccine Advisory Committee

Report Run Date: 04/24/2026 09:17:51 PM

1. Department or Agency

Department of Health and Human Services

2. Fiscal Year

2025

3. Committee or Subcommittee

National Vaccine Advisory Committee

3b. GSA Committee

No.

971

4. Is this New During Fiscal Year? 5. Current Charter 6. Expected Renewal Date 7. Expected Term Date

No 07/30/2023 07/30/2025

8a. Was Terminated During Fiscal Year? 8b. Specific Termination Authority 8c. Actual Term Date

No 42 U.S.C. 300aa-5

9. Agency Recommendation for Next Fiscal Year 10a. Legislation Req to Terminate? 10b. Legislation Pending?

Continue Not Applicable Not Applicable

11. Establishment Authority Statutory (Congress Created)

12. Specific Establishment Authority 13. Effective Date 14. Committee Type 14c. Presidential?

42 U.S.C. 300aa-5 11/14/1986 Continuing No

15. Description of Committee National Policy Issue Advisory Board

16a. Total Number of Reports

No Reports for this Fiscal Year

17a. Open 17b. Closed 17c. Partially Closed 17d. Total

Meetings and Dates

No Meetings

Current FY Next FY

18a(1). Personnel Pmts to Non-Federal Members	\$0.00	\$0.00
18a(2). Personnel Pmts to Federal Members	\$232,955.00	\$242,273.20
18a(3). Personnel Pmts to Federal Staff	\$236,636.00	\$105,873.67
18a(4). Personnel Pmts to Non-Member Consultants	\$209,925.00	\$0.00
18b(1). Travel and Per Diem to Non-Federal Members	\$0.00	\$15,000.00
18b(2). Travel and Per Diem to Federal Members	\$0.00	\$0.00
18b(3). Travel and Per Diem to Federal Staff	\$0.00	\$5,000.00
18b(4). Travel and Per Diem to Non-member Consultants	\$0.00	\$0.00
18c. Administrative Costs (FRNs, contractor support, In-person/hybrid/virtual meetings)	\$0.00	\$0.00
18d. Other (all other funds not captured by any other cost category)	\$0.00	\$0.00
18e. Total Costs	\$679,516.00	\$368,146.87
19. Federal Staff Support Years (FTE)	1.50	1.00

20a. How does the Committee accomplish its purpose?

The National Vaccine Advisory Committee (NVAC) was established in 1987 to comply with

Title XXI of the Public Health Service Act (P.L. 99-660) (Section 2105) (42 U.S. Code 300aa-5.). The NVAC serves an advisory role, providing peer review, consultation, advice, and recommendations to the Assistant Secretary for Health in his/her capacity as the Director of the National Vaccine Program, on matters related to the Program's responsibilities. Specifically, the committee studies and recommends ways to encourage the availability of an adequate supply of safe and effective vaccination products in the United States; recommends research priorities and other measures to enhance the safety and efficacy of vaccines; and discusses evidence-based strategies for preventing vaccine preventable diseases across all age groups through the use of vaccines. The committee also advises the Assistant Secretary for Health in the implementation of the National Vaccine Plan. The committee meets at least three times per year, usually in a two-day, public meeting that is available as a webcast to those unable to attend in person. Notes from each meeting are transmitted to the Assistant Secretary for Health and posted to the NVAC website at <https://www.hhs.gov/vaccines/nvac/index.html>. The committee develops reports with recommendations on topics charged by the Assistant Secretary for Health. These reports are available on the HHS website at <https://www.hhs.gov/vaccines/nvac/reports-and-recommendations/index.html>. The reports and other recommendations voiced in meetings are transmitted to the Assistant Secretary for Health as well.

20b. How does the Committee balance its membership?

The committee consists of 17 voting members. The membership is composed of 15 public

members, including the chair, and 2 members who are designated to serve as official representatives of the vaccine manufacturing industry. The public members, who are selected from individuals engaged in various aspects of the vaccine enterprise, include (but are not limited to) physicians, members of organizations concerned with immunization and representatives of state and local health departments or public health organizations. The committee membership also consists of non-voting representatives from appropriate federal agencies and non-federal entities, including state and local health agencies or public health organizations that are engaged in and/or have interest in vaccine research, the manufacture of vaccines, and immunization. Individuals who are appointed to represent federal organizations will serve as ex-officio members. Individuals who are appointed to represent non-federal entities will serve as non-voting liaison representatives.

20c. How frequent and relevant are the Committee Meetings?

The committee meets at a minimum three times a year. The committee deliberates and works to close gaps in immunization coverage areas that will have a substantial impact on public health policy and the prevention of infectious diseases and their complications through vaccination, by recommending actions to be taken -- by federal agencies and non-federal stakeholders -- that are involved in vaccine and immunization-related activities. Specifically, the committee offers advice and guidance on how to address existing barriers in the immunization delivery system, including strengthening immunization infrastructure, supporting providers and other partners who provide immunization services, increasing demand

for immunization, and fostering vaccine development and innovation in new immunization technologies.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

NVAC's mission, laid out in its charter, is very broad. NVAC is charged with advising the Assistant Secretary for Health on the entire range of vaccine and immunization policy which requires a depth of specialized expertise such as disease burden, public trust, vaccine access, and other issues affect the immunization system. Through focused and timely input, the committee plays an essential role in providing policy, research, and practice recommendations on pressing immunization issues, such as vaccine confidence, disease outbreaks, and vaccine safety. NVAC is the only federal advisory committee that considers and makes recommendations across the entire U.S. immunization system, making their work vital to improving the lagging rates of adult immunization and ensuring that we continue to immunize at rates high enough to maintain herd immunity and prevent the transmission of vaccine-preventable infectious disease.

20e. Why is it necessary to close and/or partially closed committee meetings?

Full committee meetings are open to the public.

21. Remarks

The committee did not meet in FY25. A new Chair person was not identified after the previous Chair person rotated off in September 2024.

Designated Federal Officer

Ann L. Aikin Communications Officer

Committee Members	Start	End	Occupation	Member Designation
-------------------	-------	-----	------------	--------------------

Allen, Meredith	09/13/2021	07/30/2025	Association of State and Territorial Officials (ASTHO)	Representative Member
Bobo, Matthew	02/01/2023	06/12/2025	Senior Director, Immunization	Representative Member Regular Government Employee (RGE) Member
Bok, Karin	09/12/2024	09/30/2026	FDA	Regular Government Employee (RGE) Member
Chukwuma, Uzo	01/26/2021	09/30/2025	IHS	Regular Government Employee (RGE) Member
Coyle, Rebecca	09/01/2018	07/30/2025	American Immunization Registry Association (AIRA)	Representative Member
Diba, Roxanna	06/29/2022	07/30/2025	HRSA	Regular Government Employee (RGE) Member
Duchin, Jeffrey	02/10/2022	02/09/2026	Seattle & King County Public Health Official	Special Government Employee (SGE) Member
Ehresmann, Kris	06/08/2020	12/04/2024	Epidemiologist	Special Government Employee (SGE) Member
Ford, Andrew	09/12/2024	09/30/2026	NIH	Regular Government Employee (RGE) Member
Hance, Mary Beth	02/08/2024	02/28/2026	CMS	Regular Government Employee (RGE) Member
Hannan, Claire	09/01/2019	07/30/2025	Association of Immunization Managers (AIM)	Representative Member
Henry, Erin	09/13/2023	09/26/2025	Public Health Agency of Canada (PHAC)	Representative Member
Hoft, Daniel	06/08/2020	12/04/2024	Infectious Diseases and Immunology	Special Government Employee (SGE) Member

Holbrook, Brenda	06/13/2024	06/19/2026	HRSA	Regular Government Employee (RGE) Member
Howell, Molly	02/12/2020	02/11/2025	Immunization Program Manager	Special Government Employee (SGE) Member
Johnson, Robert	09/08/2022	07/30/2025	Biomedical Advanced Research and Development Authority (BARDA)	Regular Government Employee (RGE) Member
Knighton, Troy	09/01/2018	07/30/2025	VA	Regular Government Employee (RGE) Member
Mills, Justin	09/01/2018	07/30/2025	Agency for Healthcare Research and Quality (AHRQ)	Regular Government Employee (RGE) Member
Mullen, Jewel	02/10/2022	02/09/2026	Associate Dean at Dell Medical School	Special Government Employee (SGE) Member
Patel, Mo	09/13/2023	09/30/2025	CDC	Regular Government Employee (RGE) Member
Regal, Chris	09/01/2018	07/30/2025	America's Health Insurance Plans (AHIP)	Representative Member
Rinderknecht, Stephen	02/10/2022	02/09/2026	Pediatrician	Special Government Employee (SGE) Member
Rothholz, Mitchell	06/03/2023	07/30/2025	American Pharmacists Association (APhA)	Representative Member
Schlay, Judy	06/12/2024	06/12/2026	Professor of Family Medicine	Representative Member
Srinivas, Geetha	04/29/2020	07/30/2025	USDA	Regular Government Employee (RGE) Member

Stoltzfus, Winona	02/10/2022	02/09/2026	Pediatrican	Special Government Employee (SGE) Member
Swanson, Robert	06/08/2020	12/04/2024	Public Health and Immunization Advisor	Special Government Employee (SGE) Member

Number of Committee Members Listed: 27

Narrative Description

The National Vaccine Advisory Committee (NVAC) was established in 1987 to comply with Title XXI of the Public Health Service Act (P.L. 99-660) (Section 2105) (42 U.S. Code 300aa-5). The NVAC serves an advisory role, providing peer review, consultation, advice, and recommendations to the Assistant Secretary for Health in his/her capacity as the Director of the National Vaccine Program, on matters related to the Program’s responsibilities. Specifically, the committee studies and recommends ways to encourage the availability of an adequate supply of safe and effective vaccination products in the United States; recommends research priorities and other measures to enhance the safety and efficacy of vaccines. The committee also advises the Assistant Secretary for Health in the implementation of the National Vaccine Plan.

What are the most significant program outcomes associated with this committee?

Checked if
Applies

- Improvements to health or safety
- Trust in government
- Major policy changes
- Advance in scientific research
- Effective grant making
- Improved service delivery
- Increased customer satisfaction
- Implementation of laws or regulatory requirements
- Other

Outcome Comments

NA

What are the cost savings associated with this committee?

Checked if Applies

- None
- Unable to Determine
- Under \$100,000
- \$100,000 - \$500,000
- \$500,001 - \$1,000,000
- \$1,000,001 - \$5,000,000
- \$5,000,001 - \$10,000,000
- Over \$10,000,000
- Cost Savings Other

Cost Savings Comments

NA

What is the approximate Number of recommendations produced by this committee for the life of the committee?

414

Number of Recommendations Comments

Since FY2007, the committee has approved a total of 414 individual recommendations contained within 36 sets of recommendations. These recommendations are developed through extensive subject-matter input from the NVAC subcommittees, as well as extensive deliberations by the full committee. The focus of these recommendations have included: vaccine safety and confidence; strengthening immunization information systems; improving influenza vaccination uptake in healthcare personnel; and overcoming patient and provider barriers to uptake of recommended vaccines in pregnant women; promoting research and development of vaccines for use in pregnant women. In FY 2024, the NVAC was charged with providing recommendations to inform the development of the next Vaccines National Strategic Plan and continues to work on a charge to improve vaccine innovation.

What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?

36%

% of Recommendations Fully Implemented Comments

The exact number of adopted recommendations remains to be determined. An estimate has been provided based on agency activity.

What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?

47%

% of Recommendations Partially Implemented Comments

Some recommendations have not been fully implemented due to resource limitations or remain as works in progress. Additionally, because many of the recommendations are complex, only portions have been implemented.

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

Yes No Not Applicable

Agency Feedback Comments

Feedback is provided during the NVAC meetings during remarks other informational sessions.

What other actions has the agency taken as a result of the committee's advice or recommendation?

Checked if Applies

- Reorganized Priorities
- Reallocated resources
- Issued new regulation
- Proposed legislation
- Approved grants or other payments
- Other

Action Comments

NA

Is the Committee engaged in the review of applications for grants?

No

Grant Review Comments

NA

How is access provided to the information for the Committee's documentation?

Checked if Applies

- Contact DFO
- Online Agency Web Site
- Online Committee Web Site
- Online GSA FACA Web Site
- Publications
- Other

Access Comments

N/A